Relationship between CHADS2 score and efficacy of antiarrhythmic drug therapy in patients with paroxysmal atrial fibrillation

Circulation Journal

Volumn 77, Issue 3, 2013, Pages 639-645

  Komatsu, Takashi ^a   Sato, Yoshihiro ^a   Ozawa, Mahito ^a   Kunugita, Fusanori ^a   Ueda, Hironobu ^a   Tachibana, Hideaki ^a   Morino, Yoshihiro ^a   Nakamura, Motoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; CHADS2 score; Prevention; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; APRINDINE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIBENZOLINE; DIGITALIS; DISOPYRAMIDE; FLECAINIDE; PILSICAINIDE; PIRMENOL; PROPAFENONE; VERAPAMIL; WARFARIN;

ADULT; AGED; ARTICLE; CHADS2 SCORE; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; SURVIVAL RATE; AGE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DIABETES MELLITUS; HEART FAILURE; HYPERTENSION; JAPAN; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME; ATRIAL FIBRILLATION; STROKE;

AGE FACTORS; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84874424129     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0854     Document Type: Article

References (36)

1. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: Clinical implications. J Am Coll Cardiol 2001; 37: 371-378.
2. Ohsawa M, Okayama A, Sakata K, Kato K, Itai K, Onoda T, et al. Rapid increase in estimated number of persons with atrial fibrillation in Japan: An analysis from national surveys on cardiovascular disease in 1980, 1990 and 2000. J Epidemiol 2005; 15: 194-196.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly: The Framingham study. Arch Intern Med 1987; 147: 1561-1564.
4. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials [Studies of Left Ventricular Dysfunction]. J Am Coll Cardiol 1998; 32: 695-703.
5. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation: The Framingham Study. Stroke 1996; 27: 1760-1764.
6. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American Collage/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: 700-752.
7. Sopher SM, Camm AJ. Atrial fibrillation: Maintenance of sinus rhythm versus rate control. Am J Cardiol 1996; 77: 24A-37A.
8. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2009). Hypertens Res 2009; 32: 3-107.
9. Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemias. Guidelines for diagnosis and treatment of hyperlipidemia in adults. J Jpn Atheroscler Soc 1997; 25: 1-34.
10. Komatsu T, Tachibana H, Sato Y, Ozawa M, Nakamura M, Okumura K. Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion. Circ J 2007; 71: 46-51.
11. Kodama I, Aizawa Y, Inoue H, Ohe T, Ogawa S, Okumura K, et al. The guideline for drug treatment of arrhythmia (JCS 2004). Circ J 2004; 68(Supp IV): 981-1053 (in Japanese).
12. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAFI-III clinical trials: The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30: 1223-1229.
13. van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaai RJ, Gullov AL, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163: 936-943.
14. 2 score and ischemic stroke during rhythm control therapy for paroxysmal atrial fibrillation. Int Heart J 2010; 51: 24-29.
15. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992; 20: 527-532.
16. Kato T, Yamashita T, Sagara K, Iinuma H, Fu L. Progressive nature of paroxysmal atrial fibrillation: Observation from a 14-year followup study. Circ J 2004; 68: 568-572.
17. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57: 124-127.
18. Suttorp MJ, Kingma JH, Koomen EM, van't Hof A, Tijssen JGP, Lie KI. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 1993; 71: 710-713.
19. Skoularigis J, Röthlisberger C, Skudicky D, Essop MR, Wisenbaugh T, Sareli P. Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. Am J Cardiol 1993; 72: 423-427.
20. Flaker GC, Fletcher KA, Rothbart RM, Halperin JL, Hart RG. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation: Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Am J Cardiol 1995; 76: 355-358.
21. Clair WK, Wilkinson WE, McCarthy EA, Page RL, Pritchett EL. Spontaneous occurrence of symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia in untreated patients. Circulation 1993; 87: 1114-1122.
22. Komatsu T, Yomogida K, Nakamura S, Suzuki O, Horiuchi D, Okumura K. Characteristics of the patients with paroxysmal atrial fibrillation and diabetes mellitus and long-term preventive efficacy according to antiarrhythmic drug therapy. Jpn J Electrocardiol 2005; 25: 173-180 (in Japanese).
23. Isomoto S, Fukatani M, Konoe A, Tanigawa M, Centurion OA, Seto S, et al. The influence of advancing age on the electrophysiological changes of the atrial muscle induced by programmed atrial stimulation. Jpn Circ J 1992; 56: 776-782.
24. Davies MJ, Pomerance A. Pathology of atrial fibrillation in man. Br Heart J 1972; 34: 520-525.
25. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RD, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA 1994; 271: 840-844.
26. Maisei WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91: 2D-8D.
27. Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy. JAMA 1974; 229: 1749-1754.
28. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneural blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994; 37: 449-459.
29. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al. Relationship between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109: 1509-1513.
30. Komatsu T, Tachibana H, Sato Y, Ozawa M, Kunugida F, Nakamura M. Clinical profiles, efficacy of antiarrhythmic drug therapy, and cardiovascular prognosis in patients with first-detected paroxysmal atrial fibrillation. Int Heart J 2011; 52: 32-38.
31. J-RHYTHM Registry Investigators. Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan: Subanalysis of the J-RHYTHM Registry. Circ J 2011; 75: 2357-2362.
32. Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation: A multicenter study of its status and influential factors. Circ J 2011; 75: 2087-2094.
33. Endo A, Kohsaka S, Suzuki S, Atarashi H, Kamakura S, Sakurai M, et al. Impact of drug alternation to maintain rhythm control in paroxysmal atrial fibrillation: Subanalysis from J-RHYTHM study. Circ J 2010; 74: 870-875.
34. Aizawa Y, Kohsaka S, Suzuki S, Atarashi H, Kamakura S, Sakurai M, et al. Comparison of antiarrhythmic used in patients with atrial fibrillation: Subanalysis of J-RHYTHM Study. Circ J 2010; 74: 71-76.
35. Rho RW, Page RL. Asymptomatic atrial fibrillation. Progr Cardiovasc Dis 2005; 48: 79-87.
36. Fukuda Y, Akashi M, Noma S, Mitamura H, Ogawa S. Asymptomatic recurrence of atrial fibrillation: Cardiophone-guided management. Circ J 2003; 67(Suppl I): 310.